Safety and immunogenicity of meningococcal ACWY CRM₁₉₇-conjugate vaccine in children, adolescents and adults in Russia

References

• Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine 2012; 30:Suppl 2 B3 - 9; http://dx.doi.org/10.1016/j.vaccine.2011.12.062; PMID: 22607896
   PubMed Web of Science ®Google Scholar
• Rosenstein NE, Perkins BA, Stephens DS, Popovic T, Hughes JM. Meningococcal disease. N Engl J Med 2001; 344:1378 - 88; http://dx.doi.org/10.1056/NEJM200105033441807; PMID: 11333996
   PubMed Web of Science ®Google Scholar
• Edwards MS, Baker CJ. Complications and sequelae of meningococcal infections in children. J Pediatr 1981; 99:540 - 5; http://dx.doi.org/10.1016/S0022-3476(81)80250-8; PMID: 7277093
   PubMed Web of Science ®Google Scholar
• Jafri RZ, Ali A, Messonnier NE, Tevi-Benissan C, Durrheim D, Eskola J, Fermon F, Klugman KP, Ramsay M, Sow S, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr 2013; 11:17; http://dx.doi.org/10.1186/1478-7954-11-17; PMID: 24016339
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Harrison LH, Hatcher C, Theodore J, Schmidt M, Pondo T, Arnold KE, Baumbach J, Bennett N, et al. Changes in Neisseria meningitidis disease epidemiology in the United States, 1998-2007: implications for prevention of meningococcal disease. Clin Infect Dis 2010; 50:184 - 91; http://dx.doi.org/10.1086/649209; PMID: 20001736
   PubMed Web of Science ®Google Scholar
• Tan LK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010; 362:1511 - 20; http://dx.doi.org/10.1056/NEJMra0906357; PMID: 20410516
   PubMed Web of Science ®Google Scholar
• Harrison OB, Claus H, Jiang Y, Bennett JS, Bratcher HB, Jolley KA, Corton C, Care R, Poolman JT, Zollinger WD, et al. Description and nomenclature of Neisseria meningitidis capsule locus. Emerg Infect Dis 2013; 19:566 - 73; http://dx.doi.org/10.3201/eid1904.111799; PMID: 23628376
   PubMed Web of Science ®Google Scholar
• Halperin SA, Bettinger JA, Greenwood B, Harrison LH, Jelfs J, Ladhani SN, McIntyre P, Ramsay ME, Sáfadi MA. The changing and dynamic epidemiology of meningococcal disease. Vaccine 2012; 30:Suppl 2 B26 - 36; http://dx.doi.org/10.1016/j.vaccine.2011.12.032; PMID: 22178525
   PubMed Web of Science ®Google Scholar
• Kaijalainen T, Kharit SM, Kvetnaya AS, Sirkiä K, Herva E, Parkov OV, Nohynek H. Invasive infections caused by Neisseria meningitidis, Haemophilus influenzae and Streptococcus pneumoniae among children in St Petersburg, Russia. Clin Microbiol Infect 2008; 14:507 - 10; http://dx.doi.org/10.1111/j.1469-0691.2008.01967.x; PMID: 18318743
   PubMed Web of Science ®Google Scholar
• Titova L, Samodova O, Buzinov R, Gordienko T. Epidemiology Of Meningococcal Infection In Arkhangelsk Oblast. Epinorth 2011; 11:10 - 5
   Google Scholar
• Koroleva IS, Maxina TA, Zakroeva IM, Beloshitsky GV, Lytkina IN, Pyaeva AP. Epidemiology Of Invasive Meningococcal Disease In Moscow, 2005-2010. Meningitis & Septicaemia Conference. London: Meningitis Research Foundation, 2011:39.
   Google Scholar
• Koroleva I, Beloshitskij G, Zakroeva I, Melnikova A, Koroleva M, Shipulin G, Mironov K. Invasive Meningococcal Disease In Russian Federation. 12th EMGM. Loipersdorf, Austria, 2013.
   Google Scholar
• Black SB, Plotkin SA. Meningococcal disease from the public health policy perspective. Vaccine 2012; 30:Suppl 2 B37 - 9; http://dx.doi.org/10.1016/j.vaccine.2011.12.074; PMID: 22607897
   PubMedGoogle Scholar
• O’Ryan M, Stoddard J, Toneatto D, Wassil J, Dull PM. A multi-component meningococcal serogroup B vaccine (4CMenB): the clinical development program. Drugs 2014; 74:15 - 30; http://dx.doi.org/10.1007/s40265-013-0155-7; PMID: 24338083
   PubMed Web of Science ®Google Scholar
• Meningococcal vaccines: WHO position paper, November 2011. Wkly Epidemiol Rec 2011; 86:521 - 39; PMID: 22128384
   PubMedGoogle Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE, Centers for Disease Control and Prevention (CDC). Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2013; 62:RR-2 1 - 28; PMID: 23515099
   PubMed Web of Science ®Google Scholar
• Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, et al. Immunogenicity of a tetravalent meningococcal glycoconjugate vaccine in infants: a randomized controlled trial. JAMA 2008; 299:173 - 84; http://dx.doi.org/10.1001/jama.2007.29-c; PMID: 18182599
   PubMed Web of Science ®Google Scholar
• Perrett KP, Snape MD, Ford KJ, John TM, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, et al. Immunogenicity and immune memory of a nonadjuvanted quadrivalent meningococcal glycoconjugate vaccine in infants. Pediatr Infect Dis J 2009; 28:186 - 93; http://dx.doi.org/10.1097/INF.0b013e31818e037d; PMID: 19209097
   PubMed Web of Science ®Google Scholar
• Halperin SA, Diaz-Mitoma F, Dull P, Anemona A, Ceddia F. Safety and immunogenicity of an investigational quadrivalent meningococcal conjugate vaccine after one or two doses given to infants and toddlers. Eur J Clin Microbiol Infect Dis 2010; 29:259 - 67; http://dx.doi.org/10.1007/s10096-009-0848-8; PMID: 20033465
   PubMed Web of Science ®Google Scholar
• Klein NP, Reisinger KS, Johnston W, Odrljin T, Gill CJ, Bedell L, Dull P. Safety and immunogenicity of a novel quadrivalent meningococcal CRM-conjugate vaccine given concomitantly with routine vaccinations in infants. Pediatr Infect Dis J 2012; 31:64 - 71; http://dx.doi.org/10.1097/INF.0b013e31823dce5c; PMID: 22094635
   PubMed Web of Science ®Google Scholar
• Klein NP, Shepard J, Bedell L, Odrljin T, Dull P. Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers. Vaccine 2012; 30:3929 - 36; http://dx.doi.org/10.1016/j.vaccine.2012.03.080; PMID: 22504039
   PubMed Web of Science ®Google Scholar
• Nolan TM, Nissen MD, Naz A, Shepard J, Bedell L, Hohenboken M, Odrljin T, Dull PM. Immunogenicity and safety of a CRM-conjugated meningococcal ACWY vaccine administered concomitantly with routine vaccines starting at 2 months of age. [Forthcoming] Hum Vaccin Immunother 2014; 10:280 - 9; http://dx.doi.org/10.4161/hv.27051; PMID: 24220326
   PubMed Web of Science ®Google Scholar
• Black S, Klein NP, Shah J, Bedell L, Karsten A, Dull PM. Immunogenicity and tolerability of a quadrivalent meningococcal glycoconjugate vaccine in children 2-10 years of age. Vaccine 2010; 28:657 - 63; http://dx.doi.org/10.1016/j.vaccine.2009.10.104; PMID: 19895922
   PubMed Web of Science ®Google Scholar
• Halperin SA, Gupta A, Jeanfreau R, Klein NP, Reisinger K, Walter E, Bedell L, Gill C, Dull PM. Comparison of the safety and immunogenicity of an investigational and a licensed quadrivalent meningococcal conjugate vaccine in children 2-10 years of age. Vaccine 2010; 28:7865 - 72; http://dx.doi.org/10.1016/j.vaccine.2010.09.092; PMID: 20943209
   PubMed Web of Science ®Google Scholar
• Jackson LA, Baxter R, Reisinger K, Karsten A, Shah J, Bedell L, Dull PM, V59P13 Study Group. Phase III comparison of an investigational quadrivalent meningococcal conjugate vaccine with the licensed meningococcal ACWY conjugate vaccine in adolescents. Clin Infect Dis 2009; 49:e1 - 10; http://dx.doi.org/10.1086/599117; PMID: 19476428
   PubMed Web of Science ®Google Scholar
• Jackson LA, Jacobson RM, Reisinger KS, Anemona A, Danzig LE, Dull PM. A randomized trial to determine the tolerability and immunogenicity of a quadrivalent meningococcal glycoconjugate vaccine in healthy adolescents. Pediatr Infect Dis J 2009; 28:86 - 91; http://dx.doi.org/10.1097/INF.0b013e31818a0237; PMID: 19116603
   PubMed Web of Science ®Google Scholar
• Gill CJ, Baxter R, Anemona A, Ciavarro G, Dull P. Persistence of immune responses after a single dose of Novartis meningococcal serogroup A, C, W-135 and Y CRM-197 conjugate vaccine (Menveo®) or Menactra® among healthy adolescents. Hum Vaccin 2010; 6:881 - 7; http://dx.doi.org/10.4161/hv.6.11.12849; PMID: 21339701
   PubMed Web of Science ®Google Scholar
• Arguedas A, Soley C, Loaiza C, Rincon G, Guevara S, Perez A, Porras W, Alvarado O, Aguilar L, Abdelnour A, et al. Safety and immunogenicity of one dose of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, when administered to adolescents concomitantly or sequentially with Tdap and HPV vaccines. Vaccine 2010; 28:3171 - 9; http://dx.doi.org/10.1016/j.vaccine.2010.02.045; PMID: 20189491
   PubMed Web of Science ®Google Scholar
• Jacobson RM, Jackson LA, Reisinger K, Izu A, Odrljin T, Dull PM. Antibody persistence and response to a booster dose of a quadrivalent conjugate vaccine for meningococcal disease in adolescents. Pediatr Infect Dis J 2013; 32:e170 - 7; http://dx.doi.org/10.1097/INF.0b013e318279ac38; PMID: 23114372
   PubMed Web of Science ®Google Scholar
• Reisinger KS, Baxter R, Block SL, Shah J, Bedell L, Dull PM. Quadrivalent meningococcal vaccination of adults: phase III comparison of an investigational conjugate vaccine, MenACWY-CRM, with the licensed vaccine, Menactra. Clin Vaccine Immunol 2009; 16:1810 - 5; http://dx.doi.org/10.1128/CVI.00207-09; PMID: 19812260
   PubMed Web of Science ®Google Scholar
• Gasparini R, Conversano M, Bona G, Gabutti G, Anemona A, Dull PM, Ceddia F. Randomized trial on the safety, tolerability, and immunogenicity of MenACWY-CRM, an investigational quadrivalent meningococcal glycoconjugate vaccine, administered concomitantly with a combined tetanus, reduced diphtheria, and acellular pertussis vaccine in adolescents and young adults. Clin Vaccine Immunol 2010; 17:537 - 44; http://dx.doi.org/10.1128/CVI.00436-09; PMID: 20164251
   PubMed Web of Science ®Google Scholar
• Stamboulian D, Lopardo G, Lopez P, Cortes-Barbosa C, Valencia A, Bedell L, Karsten A, Dull PM. Safety and immunogenicity of an investigational quadrivalent meningococcal CRM(197) conjugate vaccine, MenACWY-CRM, compared with licensed vaccines in adults in Latin America. Int J Infect Dis 2010; 14:e868 - 75; http://dx.doi.org/10.1016/j.ijid.2010.03.017; PMID: 20655261
   PubMed Web of Science ®Google Scholar
• Goldschneider I, Gotschlich EC, Artenstein MS. Human immunity to the meningococcus. II. Development of natural immunity. J Exp Med 1969; 129:1327 - 48; http://dx.doi.org/10.1084/jem.129.6.1327; PMID: 4977281
   PubMed Web of Science ®Google Scholar
• Gold R. Epidemiology of meningococcal disease in light of recent Hajj-associated outbreaks. Clin Infect Dis 2003; 36:684 - 6; http://dx.doi.org/10.1086/367863; PMID: 12627351
   PubMed Web of Science ®Google Scholar
• Yazdankhah SP, Caugant DA. Neisseria meningitidis: an overview of the carriage state. J Med Microbiol 2004; 53:821 - 32; http://dx.doi.org/10.1099/jmm.0.45529-0; PMID: 15314188
   PubMed Web of Science ®Google Scholar
• Wilder-Smith A, Goh KT, Barkham T, Paton NI. Hajj-associated outbreak strain of Neisseria meningitidis serogroup W135: estimates of the attack rate in a defined population and the risk of invasive disease developing in carriers. Clin Infect Dis 2003; 36:679 - 83; http://dx.doi.org/10.1086/367858; PMID: 12627350
   PubMed Web of Science ®Google Scholar
• Parent du Chatelet I, Barboza P, Taha MK. W135 invasive meningococcal infections imported from Sub-Saharan Africa to France, January to April 2012. Euro Surveill 2012; 17:17; PMID: 22687826
   PubMedGoogle Scholar
• Greenwood BM, Greenwood AM, Bradley AK, Williams K, Hassan-King M, Shenton FC, Wall RA, Hayes RJ. Factors influencing susceptibility to meningococcal disease during an epidemic in The Gambia, West Africa. J Infect 1987; 14:167 - 84; http://dx.doi.org/10.1016/S0163-4453(87)92052-4; PMID: 3106507
   PubMed Web of Science ®Google Scholar
• Cooper B, DeTora L, Stoddard J. Menveo®): a novel quadrivalent meningococcal CRM197 conjugate vaccine against serogroups A, C, W-135 and Y. Expert Rev Vaccines 2011; 10:21 - 33; http://dx.doi.org/10.1586/erv.10.147; PMID: 21162617
   PubMed Web of Science ®Google Scholar
• Rosenthal KL. Mcvittie LD. The Clinical Testing Of Preventive Vaccines. In: Mathieu M, Ed. Biological Development: A Regulatory Overview. Waltham, Ma: Paraxel, 1993:119-30.
   Google Scholar